Giovanni Grignani, MD, medical oncologist, Candiolo Cancer Institute IRCCS, discusses the intended patient population for trabectedin (Yondelis) in the treatment of sarcoma.
Giovanni Grignani, MD
Advertisement
Articles by Giovanni Grignani, MD
Giovanni Grignani, MD, medical oncologist, Candiolo Cancer Institute IRCCS, discusses the future of treatments for patients with soft tissue sarcoma.
Giovanni Grignani, MD, medical oncologist, Candiolo Cancer Institute IRCCS, discusses the safety profile of trabectedin (Yondelis) in the treatment of sarcoma.
Giovanni Grignani, MD, medical oncologist, Candiolo Cancer Institute IRCCS, discusses some of the data seen thus far with trabectedin as a treatment for patients with sarcoma.
Advertisement
Latest Updated Articles
Dr. Grignani on the Role of Trabectedin in SarcomaPublished: February 4th 2017 | Updated:
Dr. Grignani Discusses the Safety Profile of Trabectedin in SarcomaPublished: March 10th 2017 | Updated:
Dr. Grignani on the Future of Treatments for SarcomaPublished: June 8th 2017 | Updated:
Dr. Grignani on the Patient Population of Trabectedin for SarcomaPublished: June 23rd 2017 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
5